Shear Wave Elastography Versus Strain Elastography With Histogram Analysis in Solid Pancreatic Lesions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Andrada Seicean, Prof
- Phone Number: +40 787802331
- Email: andradaseicean@gmail.com
Study Contact Backup
- Name: Voicu Rednic, MD
- Phone Number: +40 721926707
- Email: rednicvoicu@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with solid pancreatic masses > 2 cm in diameter at CT scan for EUS assessment
Exclusion Criteria:
- Patients with inconclusive pathology results
- patients with cystic component > 20%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sham Comparator: Strain ratio Elastography EUS
The solid pancreatic lesion will be assessed by using strain ratio elastography EUS
|
Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
|
|
Active Comparator: Shear Wave Elastography EUS
The solid pancreatic lesion will be assessed by using shear wave elastography EUS
|
Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic sensitivity
Time Frame: 12 months
|
Comparison between the diagnostic rate in both arms
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andrada Seicean, Prof, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 396/2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.